Format

Send to

Choose Destination
Clin Pharmacol Ther. 2007 Jan;81(1):104-7.

Biomarkers and surrogate end points for fit-for-purpose development and regulatory evaluation of new drugs.

Author information

1
Merck & Co. Inc., Rahway, New Jersey, USA. wagner@merck.com

Abstract

A consistent framework for the acceptance and qualification of biomarkers for regulatory use is needed to facilitate innovative and efficient research and subsequent application of biomarkers in drug development. One key activity is biomarker qualification, a graded, "fit-for-purpose" evidentiary process linking a biomarker with biology and clinical end points. A biomarker consortium model will distribute cost and risk, and drive efficient execution of research and ultimately regulatory acceptance of biomarkers for specific indications.

PMID:
17186007
DOI:
10.1038/sj.clpt.6100017
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center